

## Efficacy of detection of significant carotid artery stenosis with TREAT imaging at 1.5T and 3.0T

H. J. Michaely<sup>1</sup>, H. Kramer<sup>1</sup>, K. Bauner<sup>1</sup>, K. Nael<sup>2</sup>, M. F. Reiser<sup>1</sup>, S. O. Schoenberg<sup>1</sup>

<sup>1</sup>Institute of Clinical Radiology, University of Munich, Munich, Bavaria, Germany, <sup>2</sup>Radiological Sciences, UCLA, Los Angeles, California, United States

### Background

In western countries, ischemic stroke is a major reason of morbidity and mortality. High-grade carotid artery stenosis (CAS) is a main risk factor for the development of stroke. Surgical treatment of high-grade CAS was proven to significantly reduce the risk of stroke in the NASCET and ECST trials<sup>1</sup>. Currently, conventional intra-arterial angiography is still considered to be the gold-standard exam for detection and grading of CAS. State-of-the-art high-spatial resolution MR-angiography (MRA) reaches a very good sensitivity and specificity for detection and grading of CAS. However, in contrast to conventional angiography, high-spatial resolution MRA does not allow to assess the hemodynamic impact of a CAS. Recently introduced MRA techniques like TREAT (time-resolved echo-shared angiographic technique) allow to monitor the passage of a contrast agent bolus with high spatial and temporal resolution. The aim of this study was therefore to evaluate the efficacy of TREAT in the detection of hemodynamically significant CAS.

### Material and Methods

40 patients (18 female /22 male, age  $69.7 \pm 9.2$ ) with suspected CAS underwent high resolution (HR)-MRA of the supraaortic vessels. HR-MRA was performed on a 1.5T MR-system (30 patients, Sonata, Siemens Medical Solution) or a 3.0T MR-system (10 patients, Tim Trio, Siemens Medical Solution) using a fast 3D-GRE sequence with parallel imaging (Voxel size  $0.9 \times 0.7 \times 0.9 \text{ mm}^3$ , parallel imaging GRAPPA factor 2, acquisition time 24s at 1.5T,  $0.8 \times 0.7 \times 0.8 \text{ mm}^3$ , GRAPPA factor 3, acquisition time 16s at 3.0T) after injection 15ml of gadobutrol (Gadovist, Schering) at 1.5ml/s. After injection of a 10ml bolus of gadobutrol, time-resolved TREAT-MRA was performed with a 3D-TREAT sequence which combines view sharing<sup>2</sup> and parallel imaging with a spiral-radial k-space reordering. The temporal resolution was 2.3s/3D-Volume (1.5T), 1.2s/3D-Volume (3.0T) respectively. The voxel size of TREAT was  $2.0 \times 1.4 \times 2.0 \text{ mm}^3$  at 1.5T and  $1.6 \times 1.5 \times 1.5 \text{ mm}^3$  at 3.0T.

The presence of CAS and the vessel area within and 2cm after the CAS was determined on multiplanar reconstructions of the high-spatial resolution MRA and the degree of stenosis (%) was measured. CAS >75% were considered hemodynamically significant. For assessment of delayed flow, signal-intensity-time curves were generated from the TREAT data on an offline workstation (Siemens Leonardo). The contralateral side served as reference for the determination of delayed flow in the stenotic vessel.

### Results

All TREAT measurements were diagnostic. In the 11 patients without CAS no flow delay was seen. 14 patients had CAS <75% and 15 patients had CAS >75%. Flow delay was identified in 3/14 patients with CAS <75% and in 12/15 patients ( $p=0.014$ ) with CAS >75%. At 1.5T, mean flow delay with CAS <75% was 0.3 frames whereas with CAS >75% the mean flow delay was 1.6 frames. With the higher temporal resolution at 3.0T, no flow delay was seen for CAS <75% and mean flow delay of 1 frame for CAS >75% (see figure 1 for two examples of high-grade CAS (arrowheads in A) with delayed flow of the affected side (arrow). C and D demonstrate the corresponding high-spatial resolution MRAs; A/C – 3.0T, B/D – 1.5T)

### Conclusion

TREAT is an easily applicable and effective tool to monitor flow delay in stenotic carotid arteries. The identification of delayed flow on TREAT imaging is highly indicative of a hemodynamically significant CAS. The higher temporal resolution at 3.0T also allows detection of minor flow delay.

### References

1. *Stroke*. 1991
2. Korosec FR, Frayne R, Grist TM, et al. *Magn Reson Med*. 1996




Figure 1 - Example of TREAT and high-spatial resolution MRA at 1.5T (B/D) and 3.0T (A/C).